Global investment attracted by companies in the longevity sector increased by more than 200% in 2024 compared to the previous year. It rose from 3.82 billion dollars in 2023 to 8.49 billion the following year, according to a report published by Longevity Investors. The analysis highlights that longevity has already become a significant standalone investment sector, with capital focused on therapies, technological platforms and personalised health solutions, and with increasingly “large” operations. Some of the most important advances in this field will be showcased from 18 to 20 February in Madrid at the fourth edition of the Longevity World Forum, a global congress held in a hybrid format—both onsite and online—bringing together leading scientists, experts and technologists in the fields of longevity and healthy ageing.
Estimates indicate that the global longevity market could surpass 8.5 billion dollars by 2027. The United States is home to 57% of the companies in the sector, acting as the centre of innovation and investment, with a well-established ecosystem of biotech firms and venture capital. In Europe, 17.3% of the sector’s companies are located on the continent.
Francisco Larrey, director of the Longevity World Forum, states that “the longevity industry is the fastest-growing industry in the world. It will have moved one-fifth of the world’s GDP by the end of 2025. The pace of technological and investment acceleration in longevity is unmatched by any other industry.”
Unlike reactive spending, investments in longevity aim to prevent or delay the onset of age-related diseases, which the Longevity Investors report highlights as a more scalable and potentially profitable model than continuing to treat advanced diseases.
According to another study carried out by the consulting firm Oliver Wyman in collaboration with the World Government Summit, the ageing market reached a global value of 600 billion dollars this year. In 2020, the figure was only 25 billion, illustrating the sector’s booming growth.
Early detection of diseases
The greatest progress, according to this analysis, is taking place in early-detection technologies, research into cellular rejuvenation and gene therapy, and in the use of Artificial Intelligence to identify ageing biomarkers and accelerate drug discovery.
“In 10 years we will be in a completely different scenario due to the speed at which AI is advancing and the growing interest of investment funds in longevity,” Larrey concludes.
More information: www.longevityworldforum.com
